383 related articles for article (PubMed ID: 15155136)
21. Targeted anti-leukemic therapy as disease-stabilizing treatment for acute myeloid leukemia relapse after allogeneic stem cell transplantation: Will it be possible to combine these strategies with retransplantation or donor lymphocyte infusions?
Reikvam H; Kittang AO; Melve G; Mosevoll KA; Bentsen PT; Ersvær E; Gjertsen BT; Bruserud Ø
Curr Cancer Drug Targets; 2013 Jan; 13(1):30-47. PubMed ID: 22873213
[TBL] [Abstract][Full Text] [Related]
22. Histone modification enzymes: novel targets for cancer drugs.
Kristeleit R; Stimson L; Workman P; Aherne W
Expert Opin Emerg Drugs; 2004 May; 9(1):135-54. PubMed ID: 15155140
[TBL] [Abstract][Full Text] [Related]
23. Autologous bone marrow transplantation as consolidation therapy in the treatment of adult patients under 60 years with acute myeloid leukaemia in first complete remission: a prospective randomized Dutch-Belgian Haemato-Oncology Co-operative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK) trial.
Breems DA; Boogaerts MA; Dekker AW; Van Putten WL; Sonneveld P; Huijgens PC; Van der Lelie J; Vellenga E; Gratwohl A; Verhoef GE; Verdonck LF; Löwenberg B
Br J Haematol; 2005 Jan; 128(1):59-65. PubMed ID: 15606550
[TBL] [Abstract][Full Text] [Related]
24. Prognostic factors and therapeutic options for relapsed or refractory acute myeloid leukemia.
Ferrara F; Palmieri S; Mele G
Haematologica; 2004 Aug; 89(8):998-1008. PubMed ID: 15339685
[TBL] [Abstract][Full Text] [Related]
25. Acute myeloid leukemia: therapeutic impact of epigenetic drugs.
Altucci L; Clarke N; Nebbioso A; Scognamiglio A; Gronemeyer H
Int J Biochem Cell Biol; 2005 Sep; 37(9):1752-62. PubMed ID: 15964234
[TBL] [Abstract][Full Text] [Related]
26. Farnesyltransferase inhibitors (FTIs) in myeloid malignancies.
Karp JE; Lancet JE
Ann Hematol; 2004; 83 Suppl 1():S87-8. PubMed ID: 15124688
[TBL] [Abstract][Full Text] [Related]
27. Human stem cell factor-antibody [anti-SCF] enhances chemotherapy cytotoxicity in human CD34+ resistant myeloid leukaemia cells.
Lu C; Hassan HT
Leuk Res; 2006 Mar; 30(3):296-302. PubMed ID: 16112192
[TBL] [Abstract][Full Text] [Related]
28. Intensive chemotherapy with mitoxantrone administered as a single injection in patients with high-risk acute myeloid leukemia: results of the EMA 2000 trial.
Thomas X; Elhamri M; Chelghoum Y; Reman O; Arnaud P; Raffoux E; Le QH; Tavernier E; Dombret H; Michallet M
Ann Hematol; 2005 Jun; 84(6):376-82. PubMed ID: 15782343
[TBL] [Abstract][Full Text] [Related]
29. Curing childhood acute myeloid leukemia (AML) at the half-way point: promises to keep and miles to go before we sleep.
Woods WG
Pediatr Blood Cancer; 2006 May; 46(5):565-9. PubMed ID: 16261562
[TBL] [Abstract][Full Text] [Related]
30. Acute myelogenous leukemia.
Shipley JL; Butera JN
Exp Hematol; 2009 Jun; 37(6):649-58. PubMed ID: 19463767
[TBL] [Abstract][Full Text] [Related]
31. Treatment of childhood acute myeloid leukemia.
ter Bals E; Kaspers GJ
Expert Rev Anticancer Ther; 2005 Oct; 5(5):917-29. PubMed ID: 16221060
[TBL] [Abstract][Full Text] [Related]
32. Emerging treatment strategies for acute myeloid leukemia (AML) in the elderly.
Kuendgen A; Germing U
Cancer Treat Rev; 2009 Apr; 35(2):97-120. PubMed ID: 18951721
[TBL] [Abstract][Full Text] [Related]
33. Incorporating novel treatment strategies into conventional therapy.
Estey EH
Clin Adv Hematol Oncol; 2009 Jun; 7(6):4-7. PubMed ID: 19645129
[No Abstract] [Full Text] [Related]
34. Limited value of FLT3 mRNA expression in the bone marrow for prognosis and monitoring of patients with acute myeloid leukemia.
Kainz B; Fonatsch C; Schwarzinger I; Sperr WR; Jäger U; Gaiger A
Haematologica; 2005 May; 90(5):695-6. PubMed ID: 15921390
[TBL] [Abstract][Full Text] [Related]
35. Molecularly targeted therapies in myelodysplastic syndromes and acute myeloid leukemias.
Morgan MA; Reuter CW
Ann Hematol; 2006 Mar; 85(3):139-63. PubMed ID: 16391911
[TBL] [Abstract][Full Text] [Related]
36. Intensified induction therapy for children with AML.
Woods WG
Ann Hematol; 2004; 83 Suppl 1():S119-20. PubMed ID: 15124701
[No Abstract] [Full Text] [Related]
37. Novel therapeutic agents in acute myeloid leukemia.
Stone RM
Exp Hematol; 2007 Apr; 35(4 Suppl 1):163-6. PubMed ID: 17379102
[TBL] [Abstract][Full Text] [Related]
38. Detailed analysis of FLT3 expression levels in acute myeloid leukemia.
Kuchenbauer F; Kern W; Schoch C; Kohlmann A; Hiddemann W; Haferlach T; Schnittger S
Haematologica; 2005 Dec; 90(12):1617-25. PubMed ID: 16330434
[TBL] [Abstract][Full Text] [Related]
39. Clinical trials in adult AML.
Stock W
Clin Adv Hematol Oncol; 2009 Jun; 7(6):8-10. PubMed ID: 19645130
[No Abstract] [Full Text] [Related]
40. Ajoene (natural garlic compound): a new anti-leukaemia agent for AML therapy.
Hassan HT
Leuk Res; 2004 Jul; 28(7):667-71. PubMed ID: 15158086
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]